ELOX PE Ratio & Valuation, Is ELOX Overvalued

Historical Valuation

Eloxx Pharmaceuticals Inc (ELOX) is now in the Fair zone, suggesting that its current forward PE ratio of 15.77 is considered Fairly compared with the five-year average of 15.77. The fair price of Eloxx Pharmaceuticals Inc (ELOX) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：11.01

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Eloxx Pharmaceuticals Inc (ELOX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Eloxx Pharmaceuticals Inc (ELOX) has a current Price-to-Book (P/B) ratio of -0.56. Compared to its 3-year average P/B ratio of -0.56, the current P/B ratio is approximately 0.00% higher. Relative to its 5-year average P/B ratio of -0.56, the current P/B ratio is about 0.00% higher. Eloxx Pharmaceuticals Inc (ELOX) has a Forward Free Cash Flow (FCF) yield of approximately -228.75%. Compared to its 3-year average FCF yield of -228.75%, the current FCF yield is approximately 0.00% lower. Relative to its 5-year average FCF yield of -228.75%, the current FCF yield is about 0.00% lower.

Performance Decomposition

AI Analysis

Market capitalization of ELOX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ELOX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ELOX currently overvalued or undervalued?

What is Eloxx Pharmaceuticals Inc (ELOX) fair value?

ELOX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Eloxx Pharmaceuticals Inc (ELOX) is between to according to relative valuation method.

How does ELOX's valuation metrics compare to the industry average?

The average P/S ratio for ELOX's competitors is 0.00, providing a benchmark for relative valuation. Eloxx Pharmaceuticals Inc Corp (ELOX) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for Eloxx Pharmaceuticals Inc (ELOX) as of Jun 10 2026?

As of Jun 10 2026, Eloxx Pharmaceuticals Inc (ELOX) has a P/B ratio of -0.56. This indicates that the market values ELOX at -0.56 times its book value.

What is the current FCF Yield for Eloxx Pharmaceuticals Inc (ELOX) as of Jun 10 2026?

As of Jun 10 2026, Eloxx Pharmaceuticals Inc (ELOX) has a FCF Yield of -228.75%. This means that for every dollar of Eloxx Pharmaceuticals Inc's market capitalization, the company generates -228.75 cents in free cash flow.

What is the current Forward P/E ratio for Eloxx Pharmaceuticals Inc (ELOX) as of Jun 10 2026?

As of Jun 10 2026, Eloxx Pharmaceuticals Inc (ELOX) has a Forward P/E ratio of 15.77. This means the market is willing to pay $15.77 for every dollar of Eloxx Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Eloxx Pharmaceuticals Inc (ELOX) as of Jun 10 2026?

As of Jun 10 2026, Eloxx Pharmaceuticals Inc (ELOX) has a Forward P/S ratio of 0.00. This means the market is valuing ELOX at $0.00 for every dollar of expected revenue over the next 12 months.

ELOX Valuation